Phase I evaluation of a weekly schedule of anguidine. Southeastern Cancer Study Group Committee on Gastrointestinal Malignancies.
A phase I evaluation of a weekly schedule of anguidine was undertaken as an alternative to the present continuous daily schedules. The dose ranged from 1.5 to 7.5 mg/m2 given as an infusion over 3 hours. No myelosuppression was noted at any dose level. The toxic effects included nausea and vomiting, hypotension, CNS symptoms (confusion, hallucinations, and psychomotor seizures), chills, fever, and diarrhea. A dose of 5 mg/m2 of anguidine produced acceptable toxicity.
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000633:toxicity; D001921:Brain / Q000187:drug effects; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007263:Infusions, Parenteral; D009369:Neoplasms / Q000188:drug therapy*; D012717:Sesquiterpenes / Q000008:administration & dosage*; D014255:Trichothecenes / Q000008:administration & dosage* / Q000633:toxicity; D014839:Vomiting / Q000139:chemically induced
D000972:Antineoplastic Agents, Phytogenic; D012717:Sesquiterpenes; D014255:Trichothecenes; C001809:diacetoxyscirpenol